COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
March 24, 2022 05:00 ET
|
COMPASS Pathways
Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...
COMPASS Pathways to participate in Cowen and Roth investor conferences
March 02, 2022 07:00 ET
|
COMPASS Pathways
LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
February 24, 2022 07:12 ET
|
COMPASS Pathways
LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and...
COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022
February 17, 2022 12:21 ET
|
COMPASS Pathways
LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
January 19, 2022 07:00 ET
|
COMPASS Pathways
London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to participate in H.C. Wainwright investor conference
January 10, 2022 07:00 ET
|
COMPASS Pathways
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
January 04, 2022 07:00 ET
|
COMPASS Pathways
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...
COMPASS Selected for Addition to NASDAQ Biotechnology Index
December 17, 2021 07:00 ET
|
COMPASS Pathways
London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways announces changes in Executive Team
December 16, 2021 07:40 ET
|
COMPASS Pathways
Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 13, 2021 07:00 ET
|
COMPASS Pathways
Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...